Raymond James Financial
CPRX

Raymond James Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Raymond James Financial’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.33M Sell
296,780
-593,160
-67% -$17.5M ﹤0.01% 2223
2026
Q1 		$21.6M Buy
889,940
+48,026
+6% +$1.14M 0.01% 1410
2025
Q4 		$19.6M Buy
841,914
+68,584
+9% +$1.53M 0.01% 1455
2025
Q3 		$15.2M Sell
773,330
-71,718
-8% -$1.47M ﹤0.01% 1607
2025
Q2 		$18.3M Buy
845,048
+404,525
+92% +$9.55M 0.01% 1438
2025
Q1 		$10.7M Buy
440,523
+110,543
+33% +$2.49M ﹤0.01% 1767
2024
Q4 		$6.89M Buy
+329,980
New +$7.09M ﹤0.01% 2108

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Raymond James Financial's CPRX Position: Q2 2026 in Review

Raymond James Financial reduced its Catalyst Pharmaceutical (CPRX) stake by 67% in Q2 2026, selling an estimated $17.5M and leaving 296,780 shares worth $9.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

Raymond James Financial first reported a position in CPRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $21.6M in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Raymond James Financial held 296,780 shares of Catalyst Pharmaceutical worth $9.33M as of Q2 2026.
  • Raymond James Financial sold 593,160 Catalyst Pharmaceutical shares in Q2 2026, an estimated $17.5M.
  • Catalyst Pharmaceutical made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2223 holding.
  • Raymond James Financial first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Catalyst Pharmaceutical position peaked at $21.6M in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.